Sunday, November 23, 2025 1:10:50 PM
Maybe you should look at is as an incorrect bear.
No reverse split was advised. As bears thought it would if the maa was rejected.
Advent was acquired by NWBO for an unbelievably reasonable sum. As bears did not think would happen.
The C-lab suite is under construction for anticipated increased scale up after commercialization. Bears forget, there is no other imminent DCvax commercial product, absolutely nothing that would cause this demand near term other than the current MAA succeeding.
Sometime in late Sept or early October, Dr. Ashkan thought an MHRA MAA decision on DCVax-l would/will be upon us in a “couple months.”
The authorized share level was increased by 900 million.
Typically CEOs are informed by regulatory agencies at necessary stages so that the company can execute its next critical preparations.
You are left with, either LP is bluffing or they are getting ready because it’s happening.
No reverse split was advised. As bears thought it would if the maa was rejected.
Advent was acquired by NWBO for an unbelievably reasonable sum. As bears did not think would happen.
The C-lab suite is under construction for anticipated increased scale up after commercialization. Bears forget, there is no other imminent DCvax commercial product, absolutely nothing that would cause this demand near term other than the current MAA succeeding.
Sometime in late Sept or early October, Dr. Ashkan thought an MHRA MAA decision on DCVax-l would/will be upon us in a “couple months.”
The authorized share level was increased by 900 million.
Typically CEOs are informed by regulatory agencies at necessary stages so that the company can execute its next critical preparations.
You are left with, either LP is bluffing or they are getting ready because it’s happening.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
